Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The closing price of TG Therapeutics Inc (NASDAQ: TGTX) was $32.91 for the day, up 4.54% from the previous closing price of $31.48. In other words, the price has increased by $4.54 from its previous closing price. On the day, 1.62 million shares were traded. TGTX stock price reached its highest trading level at $33.05 during the session, while it also had its lowest trading level at $31.33.
Ratios:
Our analysis of TGTX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.91 and its Current Ratio is at 4.59. In the meantime, Its Debt-to-Equity ratio is 1.32 whereas as Long-Term Debt/Eq ratio is at 1.31.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, TD Cowen on October 29, 2024, initiated with a Buy rating and assigned the stock a target price of $50.
On August 02, 2023, Goldman Upgraded its rating to Neutral which previously was Sell and also lowered its target price recommendation from $16 to $12.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 03 ’25 when Power Sean A sold 11,337 shares for $30.29 per share. The transaction valued at 343,443 led to the insider holds 670,632 shares of the business.
Power Sean A sold 10,021 shares of TGTX for $285,939 on Jan 06 ’25. The CFO now owns 660,611 shares after completing the transaction at $28.53 per share. On Jan 06 ’25, another insider, Power Sean A, who serves as the Officer of the company, bought 10,021 shares for $28.53 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TGTX now has a Market Capitalization of 5122934784 and an Enterprise Value of 4636496384. For the stock, the TTM Price-to-Sale (P/S) ratio is 19.35 while its Price-to-Book (P/B) ratio in mrq is 26.68. Its current Enterprise Value per Revenue stands at 17.51 whereas that against EBITDA is -11363.962.
Stock Price History:
The Beta on a monthly basis for TGTX is 2.30, which has changed by 1.190675 over the last 52 weeks, in comparison to a change of 0.2000997 over the same period for the S&P500. Over the past 52 weeks, TGTX has reached a high of $36.84, while it has fallen to a 52-week low of $12.84. The 50-Day Moving Average of the stock is 3.43%, while the 200-Day Moving Average is calculated to be 39.45%.
Shares Statistics:
TGTX traded an average of 2.92M shares per day over the past three months and 2162170 shares per day over the past ten days. A total of 155.78M shares are outstanding, with a floating share count of 140.52M. Insiders hold about 9.73% of the company’s shares, while institutions hold 66.43% stake in the company. Shares short for TGTX as of 1736899200 were 27632271 with a Short Ratio of 9.46, compared to 1734048000 on 27139751. Therefore, it implies a Short% of Shares Outstanding of 27632271 and a Short% of Float of 19.610001.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 4.0 analysts currently analyzing and rating the stock of TG Therapeutics Inc (TGTX).The consensus estimate for the next quarter is $0.12, with high estimates of $0.18 and low estimates of $0.08.
Analysts are recommending an EPS of between $0.63 and $0.01 for the fiscal current year, implying an average EPS of $0.17. EPS for the following year is $0.89, with 5.0 analysts recommending between $1.56 and $0.45.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $105.1M to a low estimate of $93.7M. As of the current estimate, TG Therapeutics Inc’s year-ago sales were $43.97MFor the next quarter, 6 analysts are estimating revenue of $116.46M. There is a high estimate of $117.8M for the next quarter, whereas the lowest estimate is $115.11M.
A total of 6 analysts have provided revenue estimates for TGTX’s current fiscal year. The highest revenue estimate was $325.9M, while the lowest revenue estimate was $314.5M, resulting in an average revenue estimate of $321.55M. In the same quarter a year ago, actual revenue was $233.66MBased on 6 analysts’ estimates, the company’s revenue will be $534.45M in the next fiscal year. The high estimate is $564.8M and the low estimate is $472.07M.
